HIGHLIGHTS
- who: Emanuel Raschi et al. from the Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum University Ospedaliero Universitaria di Bologna, Bologna, Italy have published the article: Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal, in the Journal: Pharmaceuticals 2022, 15, 645. of 22/05/2022
- what: The aim of this study was to characterize the post-marketing reporting of DILI with nintedanib and investigate the underlying pharmacological basis. To this purpose, the authors implemented a two-step strategy based on (A) the analysis of spontaneous reports submitted to the FDA`s Adverse . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.